Decoding how NSCLC patients respond and react to immunotherapy through noninvasive blood tests and tumor samples

Who could benefit from this research

What this research studies

Researchers will collect blood plasma and tumor tissue from about 300 patients across three institutions to study how tumor microenvironment patterns and CD4 T cell states relate to treatment response and toxicity. They will use noninvasive liquid biopsy techniques to quantify spatial ecosystem patterns in the tumor and link them to outcomes with immune checkpoint inhibitors. The goal is to improve prediction of who will respond and who may develop severe adverse events, enabling more personalized treatment decisions. The project builds on preliminary data suggesting linked tissue and blood signals that could guide therapy choices. The study runs over several years, with integrated analyses across multiple sites to ensure robust results.

Why it matters

Where this research is happening

• Mayo Clinic Rochester
  Rochester, United States Active

Researchers

• Principal investigator: Chaudhuri, Aadel — Mayo Clinic Rochester
• Study coordinator: Chaudhuri, Aadel

Related research

Other NIH-funded projects on the same topics.

• Using enhanced natural killer cells to treat lung cancer patients who don't respond to standard therapies

  This study is looking at a new way to help people with non-small cell lung cancer who haven't had success with current immune treatments by boosting special immune cells called NK cells to better fight the cancer.

  NIH research University of California-Irvine · Irvine, United States · NIH-11194340

• Monitoring cancer treatment response using exosomes in lung cancer patients

  This study is looking at how tiny particles in your blood, called exosomes, can help doctors see how well certain cancer treatments are working for people with non-small cell lung cancer, so they can better tailor the treatment to each patient without needing to do any painful procedures.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10890842

• Blood-based markers to identify lung cancer risk in never-smokers

  A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.

  NIH research New York University School of Medicine · New York, United States · NIH-11623223

• Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients

  This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.

  NIH research Yale University · New Haven, United States · NIH-11603643

• Integrative Analysis of Lung Cancer Risk and Its Causes

  A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.

  NIH research University of New Mexico Health Scis Ctr · Albuquerque, United States · NIH-11523887

• Integrative Analysis of Lung Cancer Risk and Causes

  A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.

  NIH research University of New Mexico Health Scis Ctr · Albuquerque, United States · NIH-11523876

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.